Immunotherapy in Sclc

Immunotherapy in Sclc small cell lung cancer(sclc) accounts for 15% of lung cancers. more than ¾ of patients have stage iv at diagnosis. since the approval of topotecanin 1996,no important clinical advances. 5years survival rate is 6%. drug developementis shifting from empirical to biological approaches. main area of interest in sclcis immune checkpoint inhibition(icpi). other targets are(parp1-aurora kinase-dll3,…). this lecture includes main studies of icpiin sclc.